Vanda Slips as FDA Rejects Therapy for Stomach Condition
Abbott Laboratories Analyst Ratings
Several value stock ETFs have reached new highs! Will the uptrend continue with the start of the interest rate cut cycle?
Nomura Securities found that after studying historical rate-cut cycles, three months after the Fed cut interest rates by 50 basis points, the performance of value stocks outperformed growth stocks.
Unmissable investment strategy! The Federal Reserve officially enters a new era of interest rate cuts, these 6 industries have the most profitable potential.
Prepare yourself for the interest rate cut cycle.
BeiGene Initiated at Outperform at JMP Securities on Strength of Brukinsa
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
ResMed Slips as Wolfe Downgrades on GLP-1 Threat From Lilly
Behind the Scenes of Merck & Co's Latest Options Trends
Sen. Sanders Says Generic Drugmakers Willing to Sell Ozempic for Less Than $100
20 S&P 500 Stocks That Move The Most When The Fed Starts Cutting Interest Rates
Over a hundred former Republican officials have written an open letter supporting Harris: Trump is not suitable to regain the White House.
① These Republican officials have served in institutions such as the White House, Department of Defense, Department of the Treasury, Department of State, Department of Justice, Department of Homeland Security, and Congress; ② These officials expressed that although there may be policy differences with Harris, compared to the "chaos and unethical behavior" displayed by Trump, these concerns are insignificant.
Comparing UnitedHealth Group With Industry Competitors In Health Care Providers & Services Industry
Amedisys Sale to UnitedHealth Unlikely to Be Done Until at Least End of November
Will these 20 dividend-paying stocks have a good opportunity for growth as the Fed is about to cut interest rates?
With the Fed cutting interest rates, not only banks and other financial companies will benefit, but non-financial giants like delta air lines and unitedhealth may also benefit from it.
Looking Into Eli Lilly's Recent Short Interest
Rhythm Pharma Draws Bullish View at JMP on Opportunity in Rare Genetic Obesities
Competitor Analysis: Evaluating Merck & Co And Competitors In Pharmaceuticals Industry
Unpacking the Latest Options Trading Trends in Eli Lilly
BioNTech Raised to Buy at Jefferies on New Cancer Drug
TransDigm, BJ's Wholesale, AbbVie And More On CNBC's 'Final Trades'